missing translation for 'onlineSavingsMsg'
Learn More
Learn More
IL-1 beta Monoclonal Antibody (1400.24.17), Invitrogen™
Mouse Monoclonal Antibody
Marque: Invitrogen MM425B
Les retours ne sont pas autorisés pour ce produit.
Afficher la politique du retour.
Description
MM425B targets IL-1 beta in WB and ELISA applications and shows reactivity with mouse samples. The MM425B immunogen is recombinant mouse IL-1 beta. MM425B detects IL-1 beta which has a predicted molecular weight of approximately 17 kDa. This product has been tested for endotoxins by limulus amoebocyte lysate (LAL) assay and contains an endotoxin concentration of less than or equal to 10 endotoxin units per milligram (EU/mg).
Interleukin-1 beta (IL-1 beta) is a proinflammatory cytokine expressed by monocytes, macrophages, and dendritic cells. IL-1 beta is synthesized in response to inflammatory stimuli as a 31 kDa inactive pro-form that accumulates in the cytosol. Cleavage of pro-IL-1 beta into the active 17 kDa protein requires the activation of inflammasomes, which are multi-protein complexes that respond to pathogens, stress conditions, and other danger signals. Inflammasome activation triggers the processing of the caspase-1 precursor into its active form, which in turn cleaves pro-IL-1 beta. IL-1 beta lacks a signal sequence peptide for classical ER/Golgi pathway and is secreted alongside caspase-1 via an alternate and incompletely understood mechanism. Although IL-1 beta is most often secreted in its active form, secretion of the uncleaved protein may be detectable under some biological conditions. IL-1 beta signals through two receptors, IL-1RI and IL-1RII, both of which are shared with IL-1 alpha. IL-1 beta activity can be moderated by IL-1 Receptor Antagonist (IL-1RA), a protein produced by many cell types that blocks receptor binding through competitive inhibition. IL-1 beta play an important role in innate host defense by triggering the production of other proinflammatory cytokines in target cells and initiating acute-phase responses to infection and injury. Elevated levels of IL-1 beta have been associated with many chronic inflammatory conditions IL-1 beta neutralizing antibodies potential therapeutic value.Spécification
IL-1 beta | |
Monoclonal | |
1.0 mg/mL | |
PBS with no preservative | |
P01584, P10749 | |
IL1B | |
Recombinant mouse IL-1 beta | |
500 μg | |
Primary | |
Human, Mouse | |
Antibody | |
IgG1 κ |
ELISA, Western Blot | |
1400.24.17 | |
Unconjugated | |
IL1B | |
catabolin; cytokine; Hematopoietin 1 (H1); IFN beta inducing factor; il 1b; IL 1β; IL-1; IL1 B; IL-1 beta; IL-1 precursor; IL1B; IL-1B; IL1B1; IL1beta; IL-1beta; IL1-BETA; IL1F2; IL1β; ILN; Interleukin; interleukin 1 beta; Interleukin 1 beta precursor; interleukin 1, beta; interleukin 1, beta 1; interleukin 1-beta; interleukin*1*beta; Interleukin1 beta; interleukin-1 beta; interleukin-1 beta precursor; interleukin-1 beta precursor (AA -113 to 153); interleukin-1 beta proprotein; interleukin-1b; interleukin-1beta; interleukin-beta; LAF; lymphocyte proliferation-potentiating factor; Osteoclast activating factor (OAF); preinterleukin 1 beta; Pro interleukin 1 beta; prointerleukin-1 beta; pro-interleukin-1-beta | |
Mouse | |
Protein A | |
RUO | |
16176, 3553 | |
-20°C | |
Liquid |